How to integrate the RetInSight Fluid Monitor & GA Monitor into your clinical routine

If you’re interested in integrating the Fluid Monitor & GA Monitor into your clinical routine, follow these steps:

1. Contact RetInSight for Information

Send us an email to contact@retinsight.com or use the contact form button below

2. Check Technical Requirements

Ensure that you have the following technical requirements in place:

  • An OCT System from Heidelberg Engineering (HE) Spectralis
  • HEYEX 2 / HEYEX PACS version 2.6
  • Should you have a different OCT/PACS system in place, we will provide you with further information on how our products can be used.

3. Choose Your Starting Option

You have two starting options to consider:

  • Temporary Demo Access:
    This option is available to get a feel for the monitors and is free of charge.
  • Full Access:
    If you plan to use the Fluid Monitor & GA Monitor in your clinical routine regularly, you can choose full access. The type of access granted depends on your monthly scan volume.

4. Sign and Return Required Documents

Depending on your chosen access level, you will need to sign and return the following documents to RetInSight:

  • Demo Access:
    – Data Processing Agreement (DPA)
    – Terms & Conditions
  • Full Access:
    – Data Processing Agreement (DPA)
    – Terms & Conditions
    – Customer Agreement

5. Gain Access to Customer Portal and Monitors on AppWay

  • After submitting the required documents, you will be granted access to the customer portal
  • To access the Monitor Apps on Heidelberg Engineering AppWay, you will need to create credentials as outlined in a step-by-step video on it that you will find in the customer portal

6. Mandatory BIT Basic Introductory Training

You are required to attend a Basic Introductory Training (BIT) session

  • This training session is essential to get started with the monitors and understand how to use them effectively in your clinical routine
  • During the training, you will be presented with key information and functionalities
  • After completing the training, you may need to verify your attendance and complete a quiz
  • It’s also an opportunity for you to ask any remaining questions you may have about using Fluid Monitor & GA Monitor

By following these steps, you can successfully integrate the Fluid Monitor & GA Monitor into your clinical routine and make the most of this valuable tool for your healthcare practice.

Contact us for further information and to get started

Contact RetInSight

Request a demo of the RetInSight Fluid Monitor

If you are interested to get a demo of the Fluid Monitor, please fill out this short form with your contact details and we will be in touch.

If you have other questions, please contact us.

We look forward to hearing from you.

References

  1. Waldstein SM, Philip AM, Leitner R, Simader C, Langs G, Gerendas BS, Schmidt-Erfurth U. Correlation of 3-Dimensionally Quantified Intraretinal and Subretinal Fluid With Visual Acuity in Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2016 Feb;134(2):182-90. doi: 10.1001/jamaophthalmol.2015.4948. PMID: 26661463.
  2. Gregor S. Reiter et al. Performance of an Artificial Intelligence Decision Support Tool, The Vienna Fluid Monitor in Neovascular Age-Related Macular Degeneration. Presentation at Euretina 2022.
  3. Gerendas, Bianca S. et al. VALIDATION OF AN AUTOMATED FLUID ALGORITHM ON REAL-WORLD DATA OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION OVER FIVE YEARS. Retina 42(9):p 1673-1682, September 2022. | DOI: 10.1097/IAE.0000000000003557.
  4. Chakravarthy, U. et al. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye 35, 2983–2990 (2021). https://doi.org/10.1038/s41433-020-01354-4
  5. Ursula Schmidt-Erfurth et al. AI-based monitoring of retinal fluid in disease activity and under therapy. Progress in Retinal and Eye Research. Volume 86, 2022, 100972, ISSN 1350-9462, https://doi.org/10.1016/j.preteyeres.2021.100972.
  6. Chaudhary, Varun et al. IMPACT OF FLUID COMPARTMENTS ON FUNCTIONAL OUTCOMES FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Literature Review. Retina 42(4):p 589-606, April 2022. DOI: 10.1097/IAE.0000000000003283.
  7. Aslam, T.M., Mahmood, S., Balaskas, K. et al. Statistical Modelling of the Visual Impact of Subretinal Fluid and Associated Features. Ophthalmol Ther 10, 127–135 (2021). https://doi.org/10.1007/s40123-020-00327-w
  8. Ursula Schmidt-Erfurth et al. Machine Learning to Analyze the Prognostic Value of Current Imaging Biomarkers in Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, Volume 2, Issue 1,2018, Pages 24-30, ISSN 2468-6530. DOI: https://doi.org/10.1016/j.oret.2017.03.015.
  9. Euretina 2021 Clinical Survey Outcomes.
  10. Data on file RetInSight.
  11. Michl M et al. A systematic evaluation of human expert agreement on optical coherence tomography biomarkers using multiple devices. Eye (Lond). 2022 Dec 28. doi: 10.1038/s41433-022-02376-w. Epub ahead of print. PMID: 36577804.
  12. Mai, Julia et al. Comparison of Fundus Autofluorescence Versus Optical Coherence Tomography-based Evaluation of the Therapeutic Response to Pegcetacoplan in Geographic Atrophy. Am J Ophthalmol. 2022 Dec;244:175-182. doi: 10.1016/j.ajo.2022.06.023. Epub 2022 Jul 16.
  13. Riedl, Sophie et al. The Effect of Pegcetacoplan Treatment on Photoreceptor Maintenance in Geographic Atrophy Monitored by Artificial Intelligence-Based OCT Analysis. Ophthalmol Retina. 2022 Nov;6(11):1009-1018. doi: 10.1016/j.oret.2022.05.030. Epub 2022 Jun 3.
  14. Vogl, Wolf-Dieter et al. Predicting Topographic Disease Progression and Treatment Response of Pegcetacoplan in Geographic Atrophy Quantified by Deep Learning. Ophthalmol Retina. 2023 Jan;7(1):4-13. doi: 10.1016/j.oret.2022.08.003. Epub 2022 Aug 7.

Clinical Decision Support System (CDSS)​

The RetInSight Fluid Monitor is a fully automated comprehensive AI-based Clinical Decision Support System, consisting of:​

  • The artificial intelligence software​
  • The web-based customer portal​
  • The Instruction for Use in the required languages​
  • The secure cloud-based image analysis server​
  • The secured data exchange via internet connection​
  • The cloud-based web service for back-end data storage and maintenance​
  • Compliance with the current EU medical device regulation ​
  • Customer support​

As a CDSS, the RetInSight Fluid Monitor facilitates decision-making in patient management, but it does not provide an autonomous recommendation.​

Request a demo of the RetInSight Fluid Monitor

If you are interested to get a demo of the Fluid Monitor, please fill out this short form with your contact details and we will be in touch.

If you have other questions, please contact us.

We look forward to hearing from you.

​